Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurobromin-decient mice

Human Molecular Genetics

Volumn 22, Issue 23, 2013, Pages 4818-4828

  Sharma, Richa ^a,c   Wu, Xiaohua ^a,c   Rhodes, Steven D ^a,c   Chen, Shi ^a,c   He, Yongzheng ^a,c   Yuan, Jin ^a,c   Li, Jiliang ^b   Yang, Xianlin ^a,c   Li, Xiaohong ^a,c   Jiang, Li ^a,c   Kim, Edward T ^c   Stevenson, David A ^d   Viskochil, David ^d   Xu, Mingjiang ^a,b,c   Yang, Feng Chun ^a,b,c  

^a Departments of Pediatrics   (United States)

^b Department of Medical and Molecular Genetics ^*  (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NEUROFIBROMIN; OSTEOCALCIN; RAS PROTEIN; TRANSCRIPTION FACTOR OSTERIX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW MONONUCLEAR CELL; BONE MASS; CELL DIFFERENTIATION; CONTROLLED STUDY; FRACTURE HEALING; HUMAN; HUMAN CELL; IN VITRO STUDY; MATURATION; MONONUCLEAR CELL; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; PSEUDARTHROSIS; SCOLIOSIS; SKELETON MALFORMATION; TIBIA FRACTURE; TIBIAL NONUNION FRACTURE;

ANIMALS; CELL LINEAGE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FLAVONOIDS; HUMANS; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OSTEOBLASTS; OSTEOCLASTS; PROTEIN KINASE INHIBITORS; PSEUDARTHROSIS; RAS PROTEINS; SIGNAL TRANSDUCTION; STEM CELLS; TIBIAL FRACTURES;

EID: 84887520191     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt333     Document Type: Article

References (69)

1. Le, L.Q. and Parada, L.F. (2007) Tumor microenvironment and neurobromatosis type I: connecting the GAPs. Oncogene, 26, 4609-4616.
2. Gutmann,D.H. (2001)The neurobromatoses:when less ismore.Hum.Mol. Genet., 10, 747-755.
3. Theos,A. andKorf, B.R. (2006) Pathophysiology of neurobromatosis type Ann. Intern. Med., 144, 842-849.
4. Xu,G.F.,O'Connell, P.,Viskochil,D.,Cawthon, R., Robertson,M.,Culver, M., Dunn, D., Stevens, J., Gesteland, R.,White, R. et al. (1990) The neurobromatosis type 1 gene encodes a protein related to GAP. Cell, 62, 599-608.
5. Atit, R.P., Crowe, M.J., Greenhalgh, D.G.,Wenstrup, R.J. and Ratner, N. (1999) The Nf1 tumor suppressor regulates mouse skin wound healing, broblast proliferation, and collagen deposited by broblasts. J. Invest. Dermatol., 112, 835-842.
6. Atit, R.P.,Mitchell, K., Nguyen, L.,Warshawsky, D. and Ratner, N. (2000 The neurobromatosis type 1 (Nf1) tumor suppressor is a modier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. J. Invest. Dermatol., 114, 1093-1100.
7. Rutkowski, J.L.,Wu, K., Gutmann, D.H., Boyer, P.J. and Legius, E. (2000 Genetic and cellular defects contributing to benign tumor formation in neurobromatosis type 1. Hum. Mol. Genet., 9, 1059-1066.
8. Zhu, Y., Ghosh, P., Charnay, P., Burns, D.K. and Parada, L.F. (2002) Neurobromas in NF1: Schwann cell origin and role of tumor environmen Science, 296, 920-922.
9. Ajuebor, M.N., Hogaboam, C.M., Kunkel, S.L., Proudfoot, A.E. and Wallace, J.L. (2001) The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J. Immunol., 166, 552-558.
10. Bajenaru,M.L.,Hernandez,M.R., Perry,A., Zhu,Y., Parada, L.F.,Garbow J.R. and Gutmann, D.H. (2003) Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63, 8573-8577.
11. Ingram, D.A., Yang, F.C., Travers, J.B.,Wenning,M.J., Hiatt, K., New, S Hood,A., Shannon,K.,Williams,D.A. andClapp,D.W. (2000)Genetic an biochemical evidence that haploinsufciency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J. Exp. Med., 191, 181-188.
12. Yang,F.C., Ingram,D.A.,Chen,S.,Hingtgen,C.M.,Ratner,N.,Monk,K.R Clegg, T.,White, H., Mead, L.,Wenning,M.J. et al. (2003) Neurobromin-decient Schwann cells secrete a potent migratory stimulu for Nf1+/- mast cells. J. Clin. Invest., 112, 1851-1861.
13. Johannessen, C.M., Reczek, E.E., James, M.F., Brems, H., Legius, E. and Cichowski, K. (2005) The NF1 tumor suppressor critically regulates TSC and mTOR. Proc. Natl Acad. Sci. USA, 102, 8573-8578.
14. Cichowski, K. and Jacks, T. (2001) NF1 Tumor suppressor gene function: narrowing the GAP. Cell, 104, 593-604.
15. Kuorilehto, T., Kinnunen, P., Nissinen, M., Alanne, M., Leskela, H.V., Lehenkari, P. and Peltonen, J. (2006) Vasculopathy in two cases of NF1-related congenital pseudarthrosis. Pathol. Res. Pract., 202, 687-690
16. Kuorilehto, T., Nissinen, M., Koivunen, J., Benson, M.D. and Peltonen, J. (2004) NF1 Tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-decient embryos. J. Bone Miner. Res., 19, 983-989.
17. Kuorilehto, T., Poyhonen, M., Bloigu, R., Heikkinen, J., Vaananen, K. an Peltonen, J. (2005) Decreased bone mineral density and content in neurobromatosis type 1: lowest local values are located in the load-carryin parts of the body. Osteoporos. Int., 16, 928-936.
18. Lammert, M., Kappler, M., Mautner, V.F., Lammert, K., Storkel, S., Friedman, J.M. and Atkins, D. (2005) Decreased bone mineral density in patients with neurobromatosis 1. Osteoporos. Int.,, 1161-1166.
19. Jacques, C. and Dietemann, J.L. (2005) Imaging features of neurobromatosis type 1. J. Neuroradiol., 32, 180-197.
20. Illes, T., Halmai, V., de Jonge, T. and Dubousset, J. (2001) Decreased bone mineral density in neurobromatosis-1 patients with spinal deformities. Osteoporos. Int., 12, 823-827.
21. Heuze,Y., Piot, B. andMercier, J. (2002) [Difcult surgicalmanagement of facial neurobromatosis type I or von Recklinghausen disease in children]. Rev. Stomatol. Chir. Maxillofac., 103, 105-113.
22. Stevenson, D.A., Moyer-Mileur, L.J., Murray, M., Slater, H., Sheng, X., Carey, J.C., Dube, B. and Viskochil, D.H. (2007) Bone mineral density in children and adolescents with neurobromatosis type 1. J. Pediatr., 150, 83-88.
23. Stevenson, D.A., Zhou, H., Ashra, S., Messiaen, L.M., Carey, J.C., D'Astous, J.L., Santora, S.D. and Viskochil, D.H. (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am. J. Hum. Genet., 79, 143-148.
24. Stevenson, D.A., Birch, P.H., Friedman, J.M., Viskochil, D.H., Balestrazzi, P., Boni, S., Buske, A., Korf, B.R., Niimura,M., Pivnick, E.K. et al. (1999) Descriptive analysis of tibial pseudarthrosis in patients with neurobromatosis 1. Am. J. Med. Genet., 84, 413-419.
25. Gilbert, A. and Brockman, R. (1995) Congenital pseudarthrosis of the tibia. Long-termfollowupof 29 cases treated bymicrovascular bone transfer.Clin. Orthop. Relat. Res., 314, 37-44.
26. Ippolito, E., Corsi, A., Grill, F.,Wientroub, S. and Bianco, P. (2000) Pathology of bone lesions associated with congenital pseudarthrosis of the leg. J. Pediatr. Orthop. B., 9, 3-10.
27. Morrissy, R.T., Riseborough, E.J. and Hall, J.E. (1981) Congenital pseudarthrosis of the tibia. J. Bone. Joint Surg. Br., 63-B, 367-375.
28. Soeld, H.A. (1971) Congenital pseudarthrosis of the tibia. Clin. Orthop. Relat. Res., 76, 33-42.
29. Wang,W., Nyman, J.S.,Moss, H.E., Gutierrez, G.,Mundy, G.R., Yang, X. and Elefteriou, F. (2010) Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts. J. Bone Miner. Res., 25, 1658-1667.
30. Schindeler, A.,Morse, A., Harry, L., Godfrey, C., Mikulec, K.,McDonald, M., Gasser, J.A. and Little, D.G. (2008)Models of tibial fracture healing in normal and Nf1-decient mice. J. Orthop. Res., 26, 1053-1060.
31. Wu, X., Chen, S., He, Y., Rhodes, S.D.,Mohammad, K.S., Li, X., Yang, X., Jiang, L., Nalepa, G., Snider, P. et al. (2011) The haploinsufcient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurobromatosis type 1. PLoS One, 6, e24917.
32. Wu, X., Estwick, S.A., Chen, S., Yu, M., Ming,W., Nebesio, T.D., Li, Y., Yuan, J., Kapur, R., Ingram, D. et al. (2006) Neurobromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/ progenitor cells. Hum. Mol. Genet., 15, 2837-2845.
33. Yang, F.C.,Chen, S.,Robling,A.G.,Yu,X.,Nebesio,T.D.,Yan, J.,Morgan, T., Li, X., Yuan, J., Hock, J. et al. (2006) Hyperactivation of p21ras and PI3 K cooperate to alter murine and human neurobromatosis type 1-haploinsufcient osteoclast functions. J. Clin. Invest., 116, 2880-2891.
34. Staser, K., Park, S.J., Rhodes, S.D., Zeng, Y., He, Y.Z., Shew, M.A., Gehlhausen, J.R., Cerabona, D., Menon, K., Chen, S. et al. (2013) Normal hematopoiesis and neurobromin-decient myeloproliferative disease require Erk. J. Clin. Invest., 123, 329-334.
35. Chang, T., Krisman, K., Theobald, E.H., Xu, J., Akutagawa, J., Lauchle, J.O., Kogan, S., Braun, B.S. and Shannon, K. (2013) SustainedMEK inhibition abrogatesmyeloproliferative disease in Nf1mutantmice. J. Clin. Invest., 123, 335-339.
36. Jessen,W.J., Miller, S.J., Jousma, E.,Wu, J., Rizvi, T.A., Brundage, M.E., Eaves, D.,Widemann, B., Kim, M.O., Dombi, E. et al. (2013)MEK Inhibition exhibits efcacy in human and mouse neurobromatosis tumors. J. Clin. Invest., 123, 340-347.
37. Mimori, K., Komaki, M., Iwasaki, K. and Ishikawa, I. (2007) Extracellular signal-regulated kinase 1/2 is involved in ascorbic acid-induced osteoblastic differentiation in periodontal ligament cells. J. Periodontol., 78, 328-334.
38. Ge, C., Xiao, G., Jiang, D. and Franceschi, R.T. (2007) Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol., 176, 709-718.
39. Kono, S.J., Oshima, Y., Hoshi, K., Bonewald, L.F., Oda, H., Nakamura, K., Kawaguchi, H. and Tanaka, S. (2007) Erk pathways negatively regulate matrix mineralization. Bone, 40, 68-74.
40. He, Y., Staser, K., Rhodes, S.D., Liu, Y.,Wu, X., Park, S.J., Yuan, J., Yang, X., Li, X., Jiang, L. et al. (2011) Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One, 6, e24780.
41. Ingram,D.A.,Hiatt, K.,King,A.J., Fisher, L., Shivakumar, R.,Derstine, C., Wenning,M.J., Diaz, B., Travers, J.B., Hood, A. et al. (2001) Hyperactivation of p21(ras) and the hematopoietic-specic Rho GTPase, Rac2, cooperate to alter the proliferation of neurobromin-decient mast cells in vivo and in vitro. J. Exp. Med., 194, 57-69.
42. Satoh,T.,Nakafuku,M.,Miyajima,A. andKaziro,Y. (1991) Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc. Natl Acad. Sci. USA, 88, 3314-3318.
43. Bourne, H.R., Sanders, D.A. and McCormick, F. (1990) The GTPase superfamily: a conserved switch for diverse cell functions. Nature, 348, 125-132.
44. Hall, A. (1992) Signal transduction through small GTPases-a tale of two GAPs. Cell, 69, 389-391.
45. Hill, C.S. and Treisman, R. (1995) Transcriptional regulation by extracellular signals: mechanisms and specicity. Cell, 80, 199-211.
46. Satoh, T., Uehara, Y. and Kaziro, Y. (1992) Inhibition of interleukin 3 and granulocyte-macrophage colony-stimulating factor stimulated increase of active ras.GTP by herbimycin A, a specic inhibitor of tyrosine kinases. J. Biol. Chem., 267, 2537-2541.
47. Stokoe, D., Macdonald, S.G., Cadwallader, K., Symons, M. and Hancock, J.F. (1994) Activation of Raf as a result of recruitment to the plasma membrane. Science, 264, 1463-1467.
48. Hall, A. (1990) The cellular functions of small GTP-binding proteins. Science, 249, 635-640.
49. Yu,X.,Chen, S., Potter,O.L.,Murthy, S.M., Li, J., Pulcini, J.M.,Ohashi,N., Winata, T., Everett, E.T., Ingram, D. et al. (2005) Neurobromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone, 36, 793-802.
50. Leevers, S.J., Paterson, H.F. andMarshall, C.J. (1994) Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature, 369, 411-414.
51. Hata, K., Ikebe, K.,Wada,M. and Nokubi, T. (2006) Osteoblast response to titanium regulates transcriptional activity of Runx2 throughMAPK pathway. J. Biomed. Mater. Res. A., 81, 446-452.
52. Hotchin, N.A. and Hall, A. (1995) The assembly of integrin adhesion complexes requires both extracellular matrix and intracellular rho/rac GTPases. J. Cell Biol., 131, 1857-1865.
53. Higuchi, C., Myoui, A., Hashimoto, N., Kuriyama, K., Yoshioka, K., Yoshikawa, H. and Itoh, K. (2002) Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J. Bone Miner. Res., 17, 1785-1794.
54. Raisz, L.G. (2005) Pathogenesis of osteoporosis: concepts, conicts, and prospects. J. Clin. Invest., 115, 3318-3325.
55. Schindeler, A., Ramachandran,M., Godfrey, C.,Morse, A.,McDonald,M., Mikulec, K. and Little, D.G. (2008)Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufcient mice. J. Orthop. Res., 26, 65-74.
56. Schindeler, A., Birke, O., Yu, N.Y.,Morse, A., Ruys, A., Baldock, P.A. and Little, D.G. (2011) Distal tibial fracture repair in a neurobromatosis type 1-decientmouse treatedwith recombinant bonemorphogenetic protein and a bisphosphonate. J. Bone Joint Surg. Br., 93, 1134-1139.
57. Kolanczyk, M., Kuhnisch, J., Kossler, N., Osswald,M., Stumpp, S., Thurisch, B., Kornak, U. and Mundlos, S. (2008) Modelling neurobromatosis type 1 tibial dysplasia and its treatment with lovastatin. BMC Med., 6, 21.
58. Gould,M.C. and Stephano, J.L. (2000) Inactivation of Ca(2+) action potential channels by theMEKinhibitorPD98059.Exp.CellRes., 260, 175- 179.
59. Sjogreen, B.,Wiklund, P. and Ekstrom, P.A. (2000)Mitogen activated protein kinase inhibition by PD98059 blocks nerve growth factor stimulated axonal outgrowth from adult mouse dorsal root ganglia in vitro. Neuroscience, 100, 407-416.
60. Jacks, T., Shih, T.S., Schmitt, E.M., Bronson, R.T., Bernards, A. and Weinberg, R.A. (1994) Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet., 7, 353-361.
61. Liu,F.,Woitge,H.W.,Braut,A.,Kronenberg,M.S.,Lichtler,A.C.,Mina,M. and Kream, B.E. (2004) Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int. J. Dev. Biol., 48, 645-653.
62. Dacquin, R., Starbuck, M., Schinke, T. and Karsenty, G. (2002) Mouse alpha1(I)-collagen promoter is the best known promoter to drive efcient Cre recombinase expression in osteoblast. Dev. Dyn., 224, 245-251.
63. Elefteriou, F., Benson, M.D., Sowa, H., Starbuck, M., Liu, X., Ron, D., Parada, L.F. and Karsenty, G. (2006) ATF4 Mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab., 4, 441-451.
64. Salvarezza, S.B., Lopez, H.S. and Masco, D.H. (2003) The same cellular signaling pathways mediate survival in sensory neurons that switch their trophic requirements during development. J. Neurochem., 85, 1347-1358.
65. Watson, K. and Fan, G.H. (2005)Macrophage inammatory protein 2 inhibits beta-amyloid peptide (1-42)-mediated hippocampal neuronal apoptosis through activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways. Mol. Pharmacol., 67, 757-765.
66. Meirelles Lda, S. and Nardi, N.B. (2003) Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization. Br. J. Haematol., 123, 702-711.
67. Hiatt, K.K., Ingram, D.A., Zhang, Y., Bollag, G. and Clapp, D.W. (2001) Neurobromin GTPase-activating protein-related domains restore normal growth in Nf12/2 cells. J. Biol. Chem., 276, 7240-7245.
68. Cheng, J., Ye, H., Liu, Z., Xu, C., Zhang, Z., Liu, Y. and Sun, Y. (2013) Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells. J. Cell Biochem., 114, 1510-1518.
69. Bergfeld, S.A. and DeClerck, Y.A. (2010) Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev., 29, 249-261.